title: A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma.
abstract: OBJECTIVE
  This phase II study evaluated the activity of combined treatment with the mTOR inhibitor everolimus and the PDGFR inhibitor imatinib in patients with previously-treated, advanced renal carcinoma. The primary endpoint was estimation of the 3-month progression-free rate.
  
  
  METHODS
  Eligible patients had metastatic or unresectable clear cell renal carcinoma, at least one prior systemic therapy, no prior mTOR inhibitor therapy, performance status 0-2, and measurable disease. Treatment consisted of everolimus 2.5 mg p.o. daily and imatinib 600 mg p.o. daily. The primary endpoint was the 3-month progression-free rate.
  
  
  RESULTS
  The study was closed after the first 19 patients because of an insufficient number of patients who were progression-free at 3 months. The 3-month progression-free rate was 49% (95% C.I. 23%, 72%) and the median progression-free survival was 2.9 months (95% C.I. 1.9, 6.2). Toxicities with an incidence of >  50% included nausea, elevated serum creatinine, edema, anemia, hypocalcemia, fatigue, diarrhea, vomiting, and dyspnea, and leukopenia.
  
  
  CONCLUSIONS
  The combination of everolimus with imatinib in previously treated patients with advanced renal carcinoma did not result in a sufficient 3-month progression-free rate to warrant further investigation of this combination.
authors.affiliation: Oregon Health and Science University Knight Cancer Institute, Portland, OR 97239, USA. ryanc@ohsu.edu
authors.forename: Christopher W
authors.initials: CW
authors.lastname: Ryan
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Vuky
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Chan
authors.forename: Zunqiu
authors.initials: Z
authors.lastname: Chen
authors.forename: Tomasz M
authors.initials: TM
authors.lastname: Beer
authors.forename: Deirdre
authors.initials: D
authors.lastname: Nauman
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D000068338:Everolimus; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D000068338:Everolimus; D020123:Sirolimus